Introduction {#S1}
============

It is well established that CD4 T cells play a significant, often central, role in the immune response to viral infections. CD4 T cells provide both "help" to enable B cells to generate effective neutralizing antibodies through affinity maturation and antibody class switching, as well as promoting the development and maintenance of cytotoxic virus-specific CD8 T cell responses. CD4 T cells have an ability to be functional memory cells and can themselves have a direct antiviral effect, although this is a lesser known role. Between 1977 and 2001, CD4 T cells with cytotoxic characteristics were described sporadically in the literature.

Initial reports of CD4 T cells with cytotoxic characteristics from cultured CD4 T cell lines and clones ([@B1]--[@B5]) were met with doubt as to whether these CD4 T cells were in fact true cytotoxic T lymphocytes (CTL), or an anomaly owing to long-term *in vitro* cultures ([@B6]). Only one report described human Leu3a+ CTL in PBMC, prior to the introduction of the CD4 nomenclature ([@B7]). The Leu3a antibody is CD4 specific, so that this report described Cytomegalovirus (CMV)-specific "helper" cells with an *ex vivo* CTL function, prior to the introduction of the CD nomenclature. From 2001, the ability of human CD4 to function as CTL *ex vivo* began to be more widely reported ([@B8]--[@B13]). Further, there is increasing evidence that cytolytic CD4 T cells (CD4 CTL) are detected following vaccinations, including against smallpox ([@B14], [@B15]), poliovirus ([@B16]), and in response to the vaccines (ALVAC/AIDSVAX) given in the RV144 HIV vaccine study ([@B17]).

Herein, we review the characteristics of CD4 CTL across a range of human viral infections including human immunodeficiency virus type 1 (HIV-1) ([@B9]--[@B11], [@B18]--[@B20]), CMV ([@B8], [@B10], [@B12], [@B21], [@B22]), Epstein--Barr virus (EBV) ([@B23]--[@B25]), influenza ([@B26], [@B27]), viral hepatitis ([@B28]), hantavirus ([@B29]), dengue ([@B30]--[@B33]), and parvovirus B19 ([@B34]). CD4 CTL may also be involved more broadly in the regulation of immune responses, through regulatory T cell (Treg) function (to be discussed later) and may also be involved in other non-viral infections and anti-tumor responses. Clearly, these cells represent an additional mechanism by which CD4 T cells contribute generally to human immunity, and below we concentrate on antiviral immunity.

Cytotoxic Effector Mechanisms {#S2}
=============================

CD4 Cytotoxicity *via* Fas Ligand {#S2-1}
---------------------------------

CD4 CTL utilize two fundamental cytotoxic effector mechanisms used also by CD8 CTL and natural killer (NK) cells. The first is the Fas/Fas ligand-mediated pathway, which involves binding of the cell surface Fas ligand (FasL; CD95L; CD178) expressed on the effector cells binding to its cognate receptor Fas (CD95) expressed on the target cells. Trimerization of Fas on the target cell leads to recruitment of the intracellular FADD/caspase 8/c-FLIP death-inducing signaling complex, and finally to caspase 3-mediated apoptotic cell death ([@B35]--[@B37]).

CD4 Cytotoxicity *via* Perforin and Granzymes {#S2-2}
---------------------------------------------

The second major mechanism of cytotoxicity is the directed exocytosis of specialized granules into target cells to induce apoptosis \[reviewed in Ref. ([@B38])\]. Cytotoxic granules were originally characterized in CD8 CTL and NK cells as large vesicles, which in turn contain numerous smaller internal vesicles and an electron dense core ([@B39]). Cytotoxic granules undergo exocytosis after specific T cell receptor (TCR) signaling; a key regulator of this process is Rab27a. Genetic defects in Rab27a result in Griscelli syndrome type 2 \[reviewed in Ref. ([@B40])\] an autosomal recessive disorder of pigmentation and severe immune deficiency ([@B41]). The pore-forming protein perforin is the best-described cytotoxic molecule in these granules ([@B42], [@B43]); it enables direct transfer of cytotoxic molecules such as granzymes and granulysin into target cells. There are five known granzymes or serine proteases in humans (A, B, H, K, and M) with various substrate specificities \[reviewed in Ref. ([@B44]--[@B47])\]. Granzyme (Gzm) A and GzmB are the most extensively studied and are the most abundant in cytotoxic granules ([@B48], [@B49]), while the other granzymes H, K, and M are less well understood. GzmA and GzmK genes are located on chromosome 5 in humans and on chromosome 13 in mice \[reviewed in Ref. ([@B50])\], and while both have tryptase-like activity, there is only partial overlap of substrates *in vivo* ([@B51]). In contrast, GzmB and GzmH (GzmC in mice) are chymases, with genes located on chromosome 14 in humans and mice \[reviewed in Ref. ([@B44])\].

Given the well-defined nature of CD8 CTL in comparison to CD4 CTL, comparisons of the cytolytic machinery of both T cell subsets can further our understanding of the relative impact of CD4 cytolytic activity in infection. In a recent murine study of lymphocytic choriomeningitis virus, Hildemann et al. used an *in vivo* CTL assay to demonstrate that CD4 CTL were readily generated and had comparable CTL activity to CD8 CTL when factors such as effector to target ratios were adjusted ([@B52]). A difference they noted between CD4 and CD8 CTL killing was the slightly delayed killing kinetics of the CD4 CTL ([@B52]). Another comparison showed that CD8 CTL stored more intracellular GzmB than CD4 T cells; however, secretion of GzmB was equivalent between both T cell subsets (although CD8 T cells secreted more perforin than CD4) ([@B53]). In our recent study of activated CD4 and CD8 T cells responding to primary HIV-1 infection and vaccination with vaccinia virus, we confirmed that CD8 T cells express significantly higher levels of perforin and T cell intracellular antigen, TIA-1 \[gene name *nkg7*, also known as granule membrane protein, GMP-17 ([@B54])\] compared to CD4 T cells ([@B15]). Despite these apparent differences in the carriage of cytolytic machinery, it would appear from the above studies that the antiviral activity of CD4 and CD8 CTL is similar.

Phenotype of CD4 CTL in Healthy Adults {#S3}
======================================

Perforin-expressing CD4 T cells identified *ex vivo* in peripheral blood from healthy humans have a distinct cell surface phenotype. These cells in healthy adults are typically CD45RO+, highly express the integrins CD11a and CD11b, and do not express the costimulatory receptors CD27 or CD28, or the chemokine receptor CCR7 ([@B9]). CD4 CTL detected in healthy human blood are not activated and are not undergoing proliferation, as they are CD38low, CD69neg, Ki67neg, and Bcl-2high ([@B9]). Also, CD4 CTL are distinct from NK T cells as they do not express CD16, CD56, or CD161 ([@B9]). CD57 expression, a marker of terminal differentiation ([@B55]), appears to be upregulated on CD4 CTL ([@B56]).

Another marker associated with CD4 CTL is Fc receptor-like 6 (FCRL6); Schreeder et al. found that FCRL6+ CD4 T cells also expressed perforin, CD57, and NKG2D ([@B57]). NKG2D, originally identified on NK cells, is a killer lectin-like receptor. Following ligation, NKG2D initiates an intracellular cascade leading to perforin exocytosis and consequently cytotoxicity. Expression of NKG2D on CD4 T cells has been suggested to occur following repeated exposures to antigen and is significantly increased in elderly (mean age: 84.3 years) compared to young (mean age: 39 years) adults ([@B58]). In contrast to CD28+ NKG2D+ CD4 T cells, their CD28null counterparts express perforin and GzmB and have a more differentiated phenotype ([@B58]). Hence, the overall phenotype of CD4 CTL in healthy adults indicate that these cells are at an advanced stage of cellular differentiation, consistent with the suggestion that these cells are generated in the presence of chronic antigen exposure ([@B56], [@B59], [@B60]). However, we and others have shown that CD4 CTL are also detected in the primary response to acute viral infections, which will be discussed later in this review. Table [1](#T1){ref-type="table"} provides a summary of the CD4 CTL phenotypes described in healthy adults, non-human primates, and mice in response to various viral infections.

###### 

**Summary of known CD4 cytotoxic T lymphocyte (CTL) phenotype and mechanism of cytolysis in human, non-human primate (NHP), and murine models**.

                                                                               Model                                      Phenotype                                                              Conditions                                                          Reference
  ---------------------------------------------------------------------------- ------------------------------------------ ---------------------------------------------------------------------- ------------------------------------------------------------------- -----------------------------------
  Healthy adults                                                               Cell surface                               CD11a/b+, CD27−, CD28− CD45RO+, CCR7−                                                                                                      Appay et al. ([@B9])
  Activation                                                                   CD38lo, CD69−, Bcl2++, Ki67−               Appay ([@B56])                                                                                                                             
  Differentiation                                                              CD57+, perforin, GzmB                      Appay et al. ([@B9]) and Appay ([@B56])                                                                                                    
  Effector                                                                     CD57+, FRCL6+, NKG2D+, perforin+           Schreeder et al. ([@B57])                                                                                                                  
  Senescence                                                                   NKG2D+                                     Alonso-Arias et al. ([@B58])                                                                                                               
                                                                                                                                                                                                                                                                     
  Regulatory T cells (Tregs)                                                   Human                                      GzmB+                                                                  *In vitro* (αCD3, αCD28, IL-2)                                      Efimova and Kelley ([@B106])
                                                                                                                                                                                                                                                                     
  Tregs                                                                        Murine                                     GzmA+, GzmB+, perforin+                                                *In vitro* phenotype (effector CD4 T-cell+ IL-2++)                  Czystowska et al. ([@B111])
                                                                                                                                                                                                                                                                     
  Infection/pathogen                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                     
  Human immunodeficiency virus type 1 (HIV-1)                                  Human                                      GzmA+, perforin+, TIA-1/GMP-17+                                                                                                            Appay et al. ([@B9])
                                                                                                                                                                                                                                                                     
  Acute HIV-1                                                                  Human                                      CD38+++, CD57−, Bcl2lo, IFN-γ, Ki67+, TIA-1+                                                                                               Zaunders et al. ([@B117])
                                                                                                                                                                                                                                                                     
  Simian immunodeficiency virus                                                NHP                                        CD28+, CD45RA−, CD95+, CCR7−, GrzmB+                                                                                                       von Gegerfelt et al. ([@B113])
                                                                                                                                                                                                                                                                     
  Cytomegalovirus (CMV)                                                        Human                                      CD28−, CD27−, GzmB+, perforin+                                         Therapy cessation                                                   van Leeuwen et al. ([@B12])
  CD27−, CD28−, perforin+                                                      Latent CMV                                 Appay et al. ([@B9])                                                                                                                       
  CD244+, CCR5+, GzmA+ IFN-γ+, TIA-1+                                          Latent CMV                                 Zaunders et al. ([@B10]) and Zaunders et al. ([@B117])                                                                                     
  CD107a, GzmA+ GzmB+, IFN-γ+, MIP-1β+, perforin+, TNF+                        Latent CMV                                 Casazza et al. ([@B21])                                                                                                                    
  CX3CR1+, Gransulysin+, GzmA/B/H+, IFN-γ+, perforin+, TNF+                    *In vitro* phenotype                       Pachnio et al. ([@B130])                                                                                                                   
  CD28−, CX3CR1+, NKG2D+, perforin+                                            Posttransplant                             Shabir et al. ([@B132])                                                                                                                    
                                                                                                                                                                                                                                                                     
  Acute CMV                                                                    Human                                      CD27−, CD28+, IFN-γ+, GrzmB+, TNF+ (acute)                                                                                                 Gamadia et al. ([@B128])
                                                                                                                                                                                                                                                                     
  Epstein--Barr virus                                                          Human                                      Eomes+Tbet+                                                            *In vitro* phenotype (CD137)                                        Akhmetzyanova et al. ([@B151])
                                                                                                                                                                                                                                                                     
  Influenza                                                                    Human                                      Perforin+, GzmB+                                                       Vaccine phenotype (BMDC, αCD3, IFN-γ, IL-2), *in vitro* phenotype   Zhou and McElhaney ([@B126])
                                                                                                                                                                                                                                                                     
  Influenza                                                                    Mouse                                      GzmB+                                                                  (CpG stimulus)                                                      Vogel and Brown ([@B164])
  GzmB+                                                                        (PR8)                                      Brown et al. ([@B72])                                                                                                                      
  Perforin+, GzmB+                                                             *In vitro* phenotype and tissue resident   Hua et al. ([@B64])                                                                                                                        
                                                                                                                                                                                                                                                                     
  Vaccinia                                                                     Human                                      CD4+ CD8− Leu11−                                                                                                                           Littaua et al. ([@B159])
  Demkowicz et al. ([@B160])                                                                                                                                                                                                                                         
  IFN-γ+ TIA-1+ CD57−                                                          Vaccine phenotype                          Zaunders et al. ([@B14])                                                                                                                   
  GrzmA, GrzmK, KLRB1/CD161, Rab27a, granulysin, TIA-1, perforin               Microarray analysis                        Munier et al. ([@B15])                                                                                                                     
                                                                                                                                                                                                                                                                     
  Ectromelia                                                                   Mouse                                      GzmB+                                                                                                                                      Fang et al. ([@B157])
                                                                                                                                                                                                                                                                     
  Hepatitis                                                                    Human                                      Perforin+                                                              Hepatitis B virus                                                   Aslan et al. ([@B28])
  Perforin+                                                                    Hepatitis C virus                          Aslan et al. ([@B28])                                                                                                                      
  Perforin++                                                                   Hepatitis D virus                          Aslan et al. ([@B28])                                                                                                                      
                                                                                                                                                                                                                                                                     
  Dengue                                                                       Human                                      Perforin+                                                              Antigen-presenting cell targets                                     Gagnon et al. ([@B77])
  Fas/FasL                                                                     HepG2 cells                                Weiskopf et al. ([@B155])                                                                                                                  
  CD45RA+ CCR6−, CCR7−, CCR4−, CXCR3−, CD8a+, CD107a+, Gzm+, Eomes+, CX3CR1+                                                                                                                                                                                         
                                                                                                                                                                                                                                                                     
  Parvovirus                                                                   Human                                      CD57+, GzmB+, perforin+, IL-17+                                        *In vitro* phenotype                                                Kumar et al. ([@B34])
                                                                                                                                                                                                                                                                     
  Hantavirus                                                                   Human                                      GzmB+, perforin+, CD107a±                                                                                                                  Ma et al. ([@B29])
                                                                                                                                                                                                                                                                     
  Human papillomavirus                                                         Human                                      CD28− NKG2D+ (CD107a and CD161 negatively correlated with frequency)                                                                       Garcia-Chagollan et al. ([@B102])

*Parentheses () indicate the conditions applied to each model, which has been linked to phenotype*.

Mechanisms Regulating CD4 CTL Development {#S4}
=========================================

Transcription Factors Conferring Cytotoxicity {#S4-1}
---------------------------------------------

It remains a matter of debate whether CD4 CTL represent a novel CD4 T cell lineage, or simply a subset of cells that have acquired cytotoxic function in addition to conventional T helper characteristics. Detailed studies have established the role of a series of transcription factors (TFs) in regulating T helper fate ([@B61]), leading to the question of whether specific TFs are also required for CD4 CTL development. The T-box family TFs T-bet and Eomesodermin (Eomes) have been known for some time as master regulators of cytotoxicity in CD8 CTL ([@B62], [@B63]); recently, studies have confirmed a role for both molecules in regulating CD4 T cell cytotoxicity as well. While T-bet expression is required for the induction of the CD4 Th1 lineage and IFN-γ production, it can also bind to the promoters of *GzmB* and *Prf1* in both CD4 and CD8 T cells ([@B64], [@B65]). During influenza infection, the binding of T-bet to cytotoxic gene promoters in CD4 T cells is regulated by Blimp-1 expression *via* a mechanism involving IL-2, type I interferons, and STAT2 signaling ([@B64]). T-bet- or Blimp-1-deficient T cells display impaired GzmB expression *in vivo*, confirming the role of these TFs in CD4 CTL activity. T-bet is not, however, the only TF involved in conferring cytotoxicity on CD4 T cells. Qui et al. were the first to demonstrate a requirement for Eomes in GzmB expression by CD4 T cells ([@B66]), although they did not assess its contribution to other mechanisms of CD4 CTL killing. To specifically dissect how expression of Eomes contributes to the generation of CD4 CTL, Eshima et al. transfected two murine CD4 T cell lines with a single copy of Eomes and assessed the expression of both perforin/granzyme and Fas/FasL cytotoxic pathways ([@B67]). Transfection of Eomes resulted in the acquisition of IFN-γ expression, upregulation of FasL upon antigenic stimulation, and expression of perforin/granzyme that lead to acquisition of cytotoxic activity. Interestingly, expression of Eomes induced cytotoxicity more efficiently than transfection with the perforin gene, suggesting that Eomes confers cytotoxicity on T cells through additional mechanisms beyond the induction of perforin expression.

A critical clue as to how Eomes is induced in CD4 CTL came from a new study by Takeuchi et al., who identified class I-restricted T cell-associated molecule (CRTAM) as a determinant of a putative CD4 CTL lineage in humans and mice ([@B68]). CRTAM, a surface membrane protein that binds the ligand cell adhesion molecule 1, is expressed on a portion of memory and naïve CD4 T cells following activation. CRTAM-expressing CD4 cells are capable of IFN-γ production under Th0 polarizing conditions, express elevated levels of Eomes and GzmB, and can differentiate into CD4 CTL *in vitro* (Figure [1](#F1){ref-type="fig"}). Intracellular signaling through the cytoplasmic domain of CRTAM is required for the expression of Eomes, IFN-γ, and GzmB/perforin in CRTAM+ cells, placing CRTAM upstream of Eomes in a signaling pathway that regulates CD4 CTL development. Interestingly, CRTAM+ CD4 cells are found preferentially in the lung and intestinal lamina propria, the same tissues in which CD4 CTL are efficiently generated during viral infections in murine models (discussed further below). The authors confirmed that viral infection increases the frequency of CRTAM+ cells in the lung and that CRTAM knock-out mice exhibit decreased CD4 CTL activity during infection. Overall, these results suggest that CRTAM+ CD4 T cells represent the precursor of CD4 CTL and identify CRTAM as both a useful marker for identifying potential CD4 CTL and a potential therapeutic target to modulate CD4 CTL activity *in vivo*.

![**Mechanisms of CD4 cytotoxic T lymphocyte (CTL) generation**. (1) Peptide stimulation in conjunction with IL-2 signaling induces CD4 CTL activity *in vitro*. (2) Interferon signaling or other inflammatory cytokine signals can synergize with or compensate for low IL-2 signaling to promote acquisition of cytolytic function. (3) The inclusion of a CxxC motif in flanking residues of the peptide antigen is thought to improve the strength of the immunological synapse and promote cytotoxicity. (4) Class I-restricted T cell-associated molecule-mediated intracellular signaling promotes Eomes expression and the acquisition of cytolytic activity.](fimmu-08-00019-g001){#F1}

While the majority of the studies described above focused on CD4 CTL isolated from peripheral blood or the lungs, Mucida et al. recently described the presence of CD4 CTL in the murine gut ([@B69]). In healthy mice, they identified a CD4 T cell population that did not express the master Th regulator ThPOK (or cKrox, encoded by *Zbtb7b*). ThPOK is responsible for inducing Th fate and repressing the expression of the CD8 CTL regulator Runx3 in thymocytes. As such, all CD4 T cells isolated from the spleen and lymph nodes of ThoPOK-reporter mice expressed ThPOK; in contrast, many CD4+ intraepithelial lymphocytes (IELs) were ThPOK− and CD8a+. These ThPOK− CD4 T cells phenotypically resembled CD8 CTL, including the expression of GzmB, CD107a, and LAMP-1, and were capable of killing *in vitro*. Interestingly, CRTAM expression was also detected on the ThPOK−CD8a+ CD4 CTL, providing additional evidence to support CRTAM as a marker of CD4 CTL in multiple tissues. The authors confirmed that the IEL CD4 CTL lost ThPOK expression post-thymically, differentiated into CD4 CTL in the context of chronic antigen exposure, and exhibited killing following antigen and IL-15 stimulation. Subsequent studies demonstrated that T-bet and Runx3 expression are responsible for driving the loss of ThPOK in IELs ([@B70], [@B71]). Overall, these data provide compelling evidence of CD4 T cell plasticity, and the ability of lineage-committed T helper cells to be re-directed toward cytotoxicity.

Cytokine Microenvironment and Antigen Stimulation {#S4-2}
-------------------------------------------------

The identification of CD4 CTL both in healthy humans and directly *ex vivo* following viral infection raises the question of how these cells are generated *in vivo*. Although this issue has been challenging to address, *in vitro* studies and insights from *in vivo* mouse experiments have provided clues to mechanisms that are likely also relevant in humans *in vivo* (Figure [1](#F1){ref-type="fig"}). Importantly, studies of influenza infection in mice have demonstrated that the generation of CD4 CTL does not necessarily require prolonged, chronic antigen stimulation, but can instead occur during acute infection ([@B72], [@B73]). Overall, it appears that the combination of a cytokine-mediated inflammatory signal and antigen presentation is required for CD4 T cells to acquire cytotoxicity ([@B69], [@B74]).

Although CD4 cytolytic activity is commonly observed in Th1 cells ([@B75]--[@B77]), CD4 CTL can be generated *in vitro* prior to full Th polarization and differentiation and do not require IFN-γ ([@B78]). IL-2, however, appears to be critical in the generation of CD4 CTL in both mice ([@B64], [@B66], [@B79]) and in *ex vivo* human peripheral blood samples ([@B80], [@B81]). In contrast, the addition of IL-4 to IL-2-stimulated cell culture inhibits the development of CD4 CTL in a dose-dependent manner. At sufficiently high antigen concentration, a low to intermediate level of cytotoxicity can be induced in the absence of IL-2, although this cytotoxic activity is primarily Fas/FasL mediated; exogenous IL-2 is required to induce perforin-mediated killing at all antigen concentrations (Figure [1](#F1){ref-type="fig"}). *In vivo*, it appears that the presence of inflammatory signals (such as pro-inflammatory cytokines or interferon signaling) during infection can compensate for, or synergize with, low IL-2 levels, leading to the generation of cytotoxic CD4 effectors. Type I interferons such as IFN-α signal through STAT2; STAT2-deficient mice exhibit significantly reduced GzmB expression in lung CD4 T cells following influenza infection, supporting the role of this pathway in generating CD4 CTL *in vivo*. Loss of interferon regulatory factor 3 also impairs GzmB expression and CD4 memory cells ([@B82]), providing further evidence for the involvement of interferon signaling in CTL induction. Workman et al. have also suggested that inflammatory cytokines such as IL-6 in the lung microenvironment may promote CD4 CTL activity, similar to the way in which CD8 CTL require signals from DCs and IL-15 during influenza infection ([@B79]). IL-15-responsiveness appears to be a trait shared by both CD4 and CD8 CTL; Mucida et al. showed that ThPOK− CD4 CTL in the murine gut remained quiescent when stimulated with only their cognate antigen, but exhibited cytotoxicity in the presence of antigen and IL-15 ([@B69]).

Modulation of antigen also impacts the functionality of CD4 CTL. Low levels of antigen generate the highest levels of cytotoxicity and produce CTL that retain the ability to express IL-5, IL-10, and IL-13; in contrast, CTL generated with higher levels of peptide produce almost exclusively IFN-γ and TNF ([@B78]). In addition to antigen concentration, characteristics of the cognate peptide can significantly impact the generation of CD4 CTL both *in vitro* and *in vivo* ([@B83]). Carlier et al. demonstrated, for several well-described epitopes in transgenic mice, that insertion of a CxxC motif into the flanking residues of a major histocompatibility complex (MHC) class II-restricted peptide results in acquisition of cytolytic activity by the antigen-specific CD4 T cell (Figure [1](#F1){ref-type="fig"}). This novel effector function is thought to occur due to an increased strength of the immunological synapse between the antigen-presenting cell (APC) and the antigen-specific CD4 T cell ([@B84]), leading to lck/ZAP70-mediated signaling, promoting T cell proliferation and expression of FasL and GzmB. Both naïve and polarized CD4 cells can acquire CTL activity through this mechanism, providing further evidence in agreement with Mucida et al. that T helper polarization is not a terminally differentiated state.

Given the particular requirements for inflammatory signaling and antigen presentation in CD4 CTL generation, it is perhaps unsurprising that some tissues appear to better promote cytolytic activity than others. During acute influenza infection, protective CD4 effectors appear to be specifically generated at the site of infection in the lung, where inflammatory signals and antigen are highly concentrated ([@B74]). Importantly, multiple studies have shown the presence of *in vivo*-generated GzmB+ CD4 CTL in the lung, but not the draining lymph nodes or spleen, at 7--8 days postinfection ([@B64], [@B72]). The microenvironment of the gut mucosa is similarly well suited to drive CD4 CTL differentiation, as the presence of local IFN-γ and IL-27 can promote T-bet expression ([@B85]). Unsurprisingly, delivery of antigen directly to mucosal tissues therefore appears to be an efficient method of eliciting CD4 CTL responses. Dutta et al. demonstrated that sterilizing immunity to homotypic influenza virus can be induced in mice through intranasal, but not intramuscular, inoculation of low-dose PR8 ([@B86]). In this model, intranasal infection was significantly more effective at inducing CD4 CTL activity in the lung than intramuscular infection, even at substantially lower infectious doses.

While these studies have provided substantial insight into the conditions under which CD4 CTL can be generated, the precise mechanisms associated with differentiation of CD4 CTL *in vivo* remain to be fully elucidated. New technology is now available to investigate single-cell transcriptomics, and future studies will likely identify transcription and repressor factors associated with typical CTL mRNAs such as for *nkg7* (TIA-1), perforin, and granzymes at the single-cell level.

Antigen Recognition by CD4 CTL and Possible Targets {#S5}
===================================================

MHC Class II-Expressing APCs {#S5-1}
----------------------------

Targets of CD4 CTL must express the MHC class II molecules. Cells that constitutively express HLA class II include APCs such as dendritic cells, macrophages including tissue-resident macrophages such as Kupffer cells in the liver, alveolar macrophages in the lungs, and B cells. The question therefore arises as to whether CD4 CTL kill APCs during normal cognate antigen interaction. DC have been described as expressing SerpinB9, which is an inhibitor of GzmB ([@B87]), but whether this prevents cytotoxicity or is involved in cross-presentation to CD8 T cells is unknown ([@B88]). Nevertheless, CD4 CTL appear to be prominent in infections that typically target APC or B cells, particularly those mediated by CMV, EBV, and dengue virus (DENV), and also HIV-1 that targets HLA class II+ activated CD4 T cells themselves, as discussed below. There are well-characterized pathways for viral-derived peptides to be presented by HLA class I on the surface of infected cells to CD8 CTL, but presentation by HLA class II on infected cells is less well characterized. HLA class II presentation by professional APC typically involves specialized endocytosis and transfer of peptides to HLA class II molecules in loading vesicles. One possible pathway for loading of viral peptides on HLA class II in infected cells may involve autophagy, and this presentation may be enhanced by IFN-γ ([@B89]).

Regardless of whether APC killing is a common function of CD4 CTL during natural viral infection, manipulation of cytolytic CD4 responses may provide interesting new avenues for immunotherapy. Carlier et al. raised CD4 CTL *in vitro* against peptides modified to contain a CxxC motif and demonstrated that these CTL are capable of inducing apoptosis in APCs, even if the APCs are presenting the original, non-CxxC-containing peptide. This approach allows for the suppression of both DC- and B cell-mediated immune responses; crucially, these CD4 CTL are also capable of killing bystander CD4 T cells that have come into contact with and are activated by the same APC, allowing an antigen-specific CD4 CTL to suppress polyclonal T cells recognizing the same APC ([@B84]).

MHC Class I-Expressing APCs {#S5-2}
---------------------------

Surprisingly, cytolytic CD4 activity has been demonstrated to occur against myeloid APCs, in a MHC class I-dependent manner ([@B90]). This function is specifically carried out by type 1 regulatory (Tr1) cells, which are CD4+ Foxp3− regulatory cells that are induced in the context of chronic antigen stimulation and IL-10 production \[recently reviewed in Ref. ([@B91], [@B92])\]. Recent identification of the Tr1 surface phentoype as CD4+ CD49b+ LAG-3+ CD226+ has greatly facilitated research into their functions ([@B93]). Tr1 cells generated *in vitro* express GzmB and perforin and are capable of killing target cells with substantially greater efficiency than other cytotoxic CD4 cells ([@B94]), possibly due to high levels of STAT3 phosphorylation ([@B95]). Magnani et al. demonstrated the perforin- and granzyme-mediated killing of myeloid APCs by Tr1 cells, which was dependent not only on HLA class I recognition but also CD2 expression and recognition of myeloid APC CD155/112 by Tr1-expressed CD226. As these cells are better defined, future studies will be able to provide a more comprehensive description of the role of cytotoxic Tr1 cells in suppressing and modulating the immune response during infection.

Epithelial Cells and Other Non-APCs {#S5-3}
-----------------------------------

Upregulation of MHC class II on murine lung epithelial cells, airway epithelial cells, or cell lines has been shown to occur following infection with Mycobacterium tuberculosis ([@B96]), influenza ([@B72]), and parainfluenza ([@B97]), respectively, as well as with IFN-γ treatment \[reviewed in Ref. ([@B13])\], which is consistent with the ability of IFN-γ to upregulate MHC class II expression *via* JAK1/JAK2 activation ([@B98]). This upregulation occurs in both bone marrow-derived and non-bone marrow-derived cells ([@B98]). These observations highlight that infections with various pathogens lead to the upregulation of MHC class II expression on multiple cell types, allowing cells other than professional APCs to provide targets for CD4 CTL. During influenza infection, the trafficking and induction of CD4 CTL in the lung coincides with the expression of MHC class II molecules on lung epithelial cells at 5 days postinfection, which is likely critical for the contribution of CD4 CTL to protection from lethal infection ([@B72]). Similarly, hepatocytes are likely targets for CD4 CTL recognition during hepatitis infection, as these cells can express class II molecules and present antigen to virus-specific CD4 cells ([@B99]). A potential role for CD4 CTL activity in mediating immunopathology is supported by the observation that two patients who spontaneously cleared Hepatitis C virus (HCV) infection exhibited a significant decrease in perforin-expressing CD4 cells that coincided with viral RNA clearance.

Virally Induced Tumors As Targets {#S5-4}
---------------------------------

Several viral infections are associated with the development of malignancies, including human papillomavirus ([@B100]) and EBV (discussed later in this review). Tumors expressing viral antigens can therefore provide important targets for CD4 CTL activity. Cervical intraepithelial neoplasia, a premalignant abnormal growth preceding cervical cancer, is negatively associated with the presence of circulating cytotoxic CD4 T cells ([@B101]). Garcia-Chagollan et al. identified a population of CD4+ CD28± NKG2D+ T-cells, which appear to be overrepresented in cervical cancer patients and which express the cytotoxic markers CD107a and CD161 ([@B102]). While the role of CD4 CTL in protection against tumor formation requires more directed study, the use of immunotherapy and vaccination to induce cytotoxic CD4 responses against tumor antigens is gaining interest, as discussed later in the review.

Tregs and Their Targets {#S5-5}
-----------------------

Regulatory T cells, similar to Tr1 cells, play important roles in the suppression and regulation of the immune response. Tregs are defined by the expression of Foxp3 and can exert regulatory function through both cytokine production (notably IL-10 and TGFβ) and contact-dependent mechanisms including CTLA-4 expression \[reviewed by Arce-Sillas et al. ([@B103])\]. Nevertheless, the requirement for GzmB, but not perforin, in contact-mediated Treg suppression was clearly demonstrated in a mouse model ([@B104]) and further mouse studies demonstrated that GzmB expression in lung Tregs regulated cellular infiltration and inflammation during respiratory syncytial virus infection ([@B105]). The function and expression of granzyme and perforin in human Tregs, however, differs in some respects from the murine system. Efimova and Kelley reported that *ex vivo*, circulating human natural Tregs (nTregs) from healthy donors do not express GzmB and require both CD3/CD28 stimulation and IL-2 treatment to upregulate GzmB expression ([@B106]). GzmB induction was dependent on the mTOR and PI3K pathway. In direct contrast, however, Grossman et al. demonstrated that nTregs stimulated with anti-CD3/CD28 and IL-2 upregulated the expression of GzmA, but not GzmB, and killed target cells *via* a perforin-dependent pathway ([@B107]). Currently, the reasons for this discrepancy are unknown and unresolved; in mice, GzmA, but not GzmB, contributes to Treg function during graft-versus-host disease ([@B108], [@B109]), raising the possibility that human Tregs may selectively express GzmA and GzmB selectively under specific circumstances.

The induction of cytotoxicity by Tregs has several consequences. First, Tregs must avoid self-inflicted apoptosis, as the expression of GzmB by nTregs has the potential to induce Treg death and prevent the suppression of target cells. In mice, Tregs concurrently upregulate both GzmB and the endogenous inhibitor serine protease inhibitor 6, which hinders Treg apoptosis and promotes suppressive activity ([@B110]). Second, both Tregs and conventional CD4 CTL can exhibit cytotoxic responses against each other. When responder CD4 T cells and Treg are cocultured in the presence of IL-2, both cell populations can upregulate GzmA, GzmB, and perforin. At low concentrations of IL-2, Tregs became susceptible to responder cell cytotoxicity and were killed. At high concentrations of IL-2, however, the Tregs maintained their suppressive activity and induced apoptosis of the responder cells ([@B111]). A similar study, focused on an effector population of nTregs expressing HLA-DR, also demonstrated the capacity of responder CD4 cells to upregulate expression of GzmB after TCR stimulation and kill Tregs ([@B112]). Together, these studies demonstrate the myriad of pathways through which CD4 cytolytic activity can play either a suppressive function or promote escape from regulatory responses.

Infections in Which CD4 CTL are Protective {#S6}
==========================================

Simian Immunodeficiency Virus {#S6-1}
-----------------------------

Antiviral CD4 CTL have been found in the response to simian immunodeficiency virus (SIV) infection of rhesus macaques. SIV-infected macaques controlling viral replication were depleted of CD8 T cells, leading to increased viremia that was rapidly controlled despite the lack of SIV-specific CD8 T cells ([@B113]). Viral control was associated with antibody responses and expansion of circulating SIV-specific CD4 T cells that were CD45RA− CD28+ CD95+ CCR7− and expressed GzmB ([@B113]). In a very similar study, Sacha et al. depleted CD8 T cells from elite controlling macaques and found robust Gag- and Nef-specific CD4 T cell responses during the re-establishment of viral control ([@B114]). Interestingly, the SIV-specific CD4 T cells did not control viral replication in CD4 T cells *ex vivo*; however, they did recognize and eliminate SIV-infected macrophages ([@B114]). A recent comparison of monkey species in which SIV infection is either pathogenic or non-pathogenic found higher GzmB expression in CD4 T cells from pathogenic rhesus macaques (pathogenic infection) compared to African green monkeys (non-pathogenic infection) ([@B115]). Ayala et al. very recently demonstrated cytolytic activity from an SIV Gag-specific CD4 T cell clone that could control viral replication in other CD4 T cells as well as itself ([@B116]).

Human Immunodeficiency Virus {#S6-2}
----------------------------

Activated CD4 T cells are the major targets of the HIV-1, and a proportion of HIV-specific CD4 T cells are infected and lost. Despite this, CD4 T cells with a cytotoxic profile are expanded in HIV-1-infected individuals. Compared to controls, Appay et al. showed that HIV-infected individuals exhibited higher numbers of CD4 T cells expressing perforin, GzmA, and GMP-17/TIA-1 ([@B9]). Although these cells were detected early in infection, the highest numbers were found in individuals with chronic infection. The mechanism of cytotoxicity appeared to be primarily perforin mediated ([@B9]). Over the years, a number of groups have studied CD4 CTL during different stages of HIV-1 infection. During very early untreated primary HIV-1 infection (PHI; \<22 days after the onset of symptoms), Zaunders et al. detected a 10- to 20-fold increase in the proportion of bulk CD4 T cells that were highly activated (CD38+++), proliferating (Ki-67+), and expressed the HIV-1 co-receptor CCR5 as well as GMP-17/TIA-1, perforin, and GzmB ([@B117]). Within the same group of PHI individuals, Gag-specific IFN-γ+ CD4 T cells exhibited a similar CD38+++, Ki-67+, Bcl-2 low, CD57−, GMP-17/TIA-1+ phenotype ([@B117]). We recently confirmed in a second group of individuals with untreated PHI that CD4 T cells are consistently highly activated and express perforin, GMP-17/TIA-1, GzmB, and GzmK ([@B15]). Recently, Johnson et al. characterized HIV-specific CD107a+ CD4 T cells from individuals with PHI using Fluidigm analysis. They found that CD107a+ IFN-γ+ CD4 T cells shared a transcriptional profile with HIV-specific CD8 CTL, including expression of Gzms A, B, K, and perforin; importantly, the HIV-specific CD107a+ CD4 T cells exhibited similar killing activity to HIV-specific CD8 CTL ([@B20]).

Importantly, CD4 CTL emerge early during HIV-1 infection, correlate with acute viral load, and are associated with early viral load set point ([@B20]). Soghoian et al. performed a longitudinal study of untreated individuals with early PHI and found that individuals who controlled viral replication within 12 months of infection had a significant expansion of HIV-specific CD4 T cells compared to individuals who progressed to higher viral set points ([@B19]). Viral controllers had higher expression of the degranulation marker CD107a on Gag-specific CD4 T cells compared to non-controllers, and GzmA+ HIV-specific CD4 T cell responses at baseline were predictive of slower disease progression ([@B19]). Together, these studies clearly support a role for CD4 CTL in controlling early viral replication and contributing to delayed disease progression.

CD4 CTL may confer protection from disease progression through several mechanisms. First, p24 and Nef-specific CD4 CTL can suppress HIV replication in both macrophages and T cells *in vitro* ([@B10], [@B11], [@B118]). In several cases, these CTL responses have been characterized in long-term non-progressors, who have been infected with HIV-1 but have remained asymptomatic for many years. In one such individual, Zaunders et al. identified a very large expansion of circulating CD4 T cells specific for p24, expressing CCR5 and the cytotoxic markers GMP-17/T1A-1, GzmA, and GzmB, that represented 5% of CD4 T cells in this individual ([@B10]). No cytotoxic activity was observed *ex vivo*; however, following a 10-day expansion with individual Gag peptides, purified CD4 T cells demonstrated peptide-specific cytotoxicity at even low effector to target ratios ([@B10]). Interestingly, these HIV-specific CD4 T cells had originally been identified by their dramatic ability to proliferate *in vitro* in response to p24 ([@B119]--[@B121]). Second, CD4 CTL may provide immunological pressure on HIV, similar to the well-documented impact of virus-specific CD8 CTL, which can lead to viral escape. Despite the apparent importance of CD4 CTL in the anti-HIV response, a conundrum for many researchers has been why viral escape from CD4 CTL pressure has not been widely identified. Considerable efforts have been made to demonstrate this phenomenon with very few cases noted in the literature. Harcourt et al. described viral variants to p24 and p17 Gag epitopes in the proviral DNA of an HIV+ individual, the epitope variation did not diminish class II binding but were unable to stimulate proliferation of fresh PBMCs or cultured T cell lines ([@B122]). More recently, Burwitz et al. studied an elite controlling rhesus macaque that lost viral control and found that post-breakthrough sequencing identified a mutation in Gag p27 targeted by CD4 CTL, indicating the CD4 CTL were able to exert strong immune pressure *in vivo* ([@B123]).

Influenza {#S6-3}
---------

As previously discussed, multiple groups have shown that CD4 CTL are generated following acute influenza infection \[recently reviewed in Ref. ([@B27], [@B124])\]. Influenza-specific CD4+ CTL were described as early as 1985 by Lukacher et al. ([@B125]), and further characterized a decade later when Graham et al. ([@B75]) demonstrated protective cytolytic activity in Th1, but not Th2, influenza-specific T cell clones in mice. The precise mechanisms by which CD4 T cells can provide protection against lethal or highly pathogenic influenza infection were identified in a transgenic mouse model of PR8 infection. *In vitro* primed CD4 effector cells adoptively transferred into naïve recipients provided protection in an IFN-γ-independent manner by (A) promoting B cell maturation and antibody production and (B) perforin-mediated cytolytic activity ([@B74]). It was further shown that while antibody production was required in the later stages of infection to fully clear the virus, CD4 cytotoxicity was required earlier in infection to control viral replication. Cytolytic activity was Fas/FasL-independent and required the expression of perforin to provide protection, as demonstrated by perforin^−/−^ effectors. Both Brown et al. ([@B72]) and McKinstry et al. ([@B73]) extended this work, demonstrating that CD4 effectors generated *in vivo* from the lungs of mice given a sublethal PR8 infection could similarly provide protection from lethal infection when transferred to naïve recipient mice. In these studies, CD4 perforin expression not only contributed to recovery and viral control following infection ([@B72], [@B73]) but exerted selective pressure leading to viral escape mutations ([@B73]). Those *in vivo*-generated CD4 CTL can provide the same protection from infection as *in vitro*-generated cells provide evidence that the *in vitro* protocols use to induce CD4 cytotoxicity do approximate the mechanisms that lead to naturally occurring CD4 CTL clones.

Influenza-specific CD4 CTL have been identified in human subjects, even in the absence of strain-specific antibodies ([@B26]). Preexisting CD4 T cell responses were primarily directed toward the nucleoprotein and matrix protein, which tend to be conserved between strains, and expanded significantly following subsequent viral challenge. Importantly, the frequency of baseline CD4 responses correlated inversely with illness severity following infection, while the expansion of these responses 7 days post-challenge tracked with viral load and illness duration. Further characterization of baseline CD4 responses confirmed the ability of influenza-specific cells to perform perforin/granzyme-mediate killing of B cell targets. Similar CD4 CTL responses are induced in humans following seasonal influenza vaccination ([@B126]). Although CD8 CTL vaccine responses are compromised in older adults compared to younger subjects by 10 weeks postvaccination, CD4 cytolytic activity was comparable between all age groups, suggesting that the CD4 CTL response may be more durable in elderly persons. This is consistent with the observation that NKG2D+ CD4 T cells accumulate with age ([@B58]), potentially reflecting a preference for CD4 CTL responses in the elderly. Mouse models support this idea, as aged mice exhibited delayed, but higher magnitude, CD4 CTL activity during influenza infection compared to younger mice ([@B127]). Additional studies specifically tracking CD4 CTL activity to various infections or vaccines in young and elderly adults will provide further insight into this observation.

Cytomegalovirus {#S6-4}
---------------

Infection with human herpesvirus 5, otherwise known as CMV, leads to lifelong asymptomatic infection in healthy hosts. However, in the immunocompromised host such as transplant recipients or untreated HIV-infected individuals, CMV causes serious disease. CMV infects endothelial, epithelial, and glial cells *in vivo*, all of which express MHC class II molecules, particularly following induction by IFN-γ. During primary CMV infection in adults, CMV-specific CD4 T cells have been associated with better clinical outcome ([@B128]). These circulating CMV-specific CD4 T cells displayed an effector memory phenotype and produced the Th1 cytokines IFN-γ and TNF, as well as GzmB ([@B59]). Following cessation of viral load in primary CMV infection, a population of CD28^−^CD27^−^ CD4 T cells expressing perforin and GzmB have been found to emerge and expand in the circulation of infected individuals ([@B12]).

During latent infection, Suni et al. found that CMV-specific CD4 T cells were CD4+CD8^dim^ ([@B8]), and Appay et al. showed that these cells were CD28^−^CD27^−^([@B9]) and expressed perforin. Zaunders et al. showed a high proportion of IFN-γ+ CMV-specific CD4 T cells expressed GMP-17/TIA-1; furthermore, a subset of circulating CD4 T cells from CMV-seropositive adults expressed CCR5, GMP-17/TIA-1, GzmA, and CD244, with low expression of GzmB and perforin ([@B10]). Purified CD4+ CD8^dim^ T cells possessed higher CMV-specific cytotoxicity compared to their CD4+ CD8^−^ counterparts and were able to lyse whole CMV-loaded EBV-transformed B lymphoblastoid cells *ex vivo* ([@B8]). During this latent stage of infection, van Leewen et al. showed that CD4+ CD28− T cells emerged with immediate cytotoxic capacity, that these cells could lyse CMV antigen expressing target cells in a class II-dependent manner, and that CD28− CD4 CTL clones common during latency were rare or absent during early infection ([@B129]). Casazza et al. hypothesized that CD4 T cells detected during chronic subclinical CMV infection expressed a specific effector phenotype. They revealed that CMV-specific CD4 T cells expressed IFN-γ, TNF, and MIP-1β in the absence of IL-2, had direct cytolytic activity (CD107a, perforin, GzmA, and B expression), and had a terminally differentiated phenotype ([@B21]). They suggested that the lack of IL-2 expression indicates that these CD4 T cells are not present to provide "help" but more likely to have a direct antiviral effect.

Very recently, Pachnio et al. confirmed that CMV-specific CD4 T cells possessed a highly differentiated effector memory phenotype and expressed IFN-γ, TNF, and MIP-1β. Using HLA class II tetramers to characterize CMV-specific CD4 T cells, they found that these cells had an "intense" cytotoxic profile; microarray analysis revealed an upregulation of genes associated with cytotoxic function, such as Gzms A, B, H, granulysin, and perforin, and that these cells also expressed CX3CR1 (a marker of endothelial homing) ([@B130]). CMV-specific CD4 CTL showed strong cytotoxic activity *ex vivo* against antigen-loaded targets ([@B130]). The same class II tetramer was used by Raeiszadeh et al. to demonstrate CMV-specific CD4 T cell reconstitution following stem cell transplantation; these cells had an effector memory phenotype and contained cytotoxic molecules ([@B131]). Shabir et al. followed an unselected group of kidney transplant recipients and examined the CD28− CD4 T cells. These cells were found predominantly in CMV-seropositive patients and expanded posttransplantation; they had an effector memory phenotype and expressed CX3CR1 as well as NKG2D and perforin ([@B132]).

Murine CMV (MCMV) {#S6-5}
-----------------

In MCMV, mice lacking CD4 T cells were shown to have an impaired ability to clear virus from the salivary glands, an important site of viral latency ([@B133]). Walton et al. revealed that the mechanism of CD4 T cell immune control in the salivary glands of MCMV infected mice was *via* direct secretion of IFN-γ, which induced antiviral signaling on non-hematopoietic cells ([@B134]). Adoptive transfer experiments of MCMV-specific effector CD4 T cells to immune-compromised mice was found to be protective during pathogenic MCMV infection and IFN-γ was a vital mediator of this protective capacity ([@B135]). Despite the apparent importance of CD4 T cells in viral control in the above studies, there was no specific link to CD4 CTL. Verma et al. have recently utilized MHC II tetramers to phenotypically and functionally characterize the two first reported I-A^d^-restricted CD4 T cell responses specific for MCMV. They show MCMV-specific CD4 T cells in the liver express higher levels of GzmB than the same cells in the spleen. The organ-dependent expression of GzmB is reflected in *in vivo* CD4 CTL activity, with higher target cell loss in the liver compared to spleen. The data presented in this study suggest that MCMV-specific CD4 T cells can kill target cells in an epitope- and organ-specific manner. Additionally, they show that vaccination with CD4 T cell epitopes leads to reduced viral replication in tissues where CD4 CTL are observed ([@B136]).

Hantavirus {#S6-6}
----------

Haantan virus belongs to the *Bunyaviridae* family, and like other viruses in that family, can cause hemorrhagic fever with renal syndrome (HFRS). Screening of CD4 responses with peptide pools derived from the NTNV glycoprotein revealed a subset of virus-specific CD4 cells that expressed GzmB, perforin, and/or CD107a ([@B29]). These cells were found at significantly higher frequencies and exhibited greater cytotoxicity among patients with mild/moderate disease compared to those with severe or critical illness. Furthermore, the frequency of GzmB+ CD4 cells correlated inversely with RNA load during acute HFRS, suggesting a potential impact of CD4 CTL responses in the control of infection.

Infections That Evade CD4 CTL Responses {#S7}
=======================================

Epstein--Barr Virus {#S7-1}
-------------------

Epstein--Barr virus is a ubiquitous herpesvirus that infects 95% of the human population by adulthood ([@B137]), taking the form of infectious mononucleosis in the acute phase. The high global prevalence of EBV infection results in EBV accounting for a 1% worldwide cancer incidence rate, with Hodgkin lymphoma, non-Hodgkin lymphoma, nasopharyngeal carcinoma, and gastric cancers being the most common EBV-associated malignancies ([@B138]). The identification of cytotoxic EBV-specific CD4 responses dates back to 1984 ([@B139]), and similar responses have been identified in the mouse model of infection with γ-herpesvirus 68, in which cytolytic killing of virally infected cells by CD4 T cells has been observed *in vivo* ([@B140], [@B141]). Much of the work in this field has focused on identifying EBV epitopes from various stages of the lytic and latent phases of infection that may overcome viral immune evasion. Multiple studies have described CD4 CTL responses against latent-cycle antigens that evade recognition by CD8 CTL ([@B142]--[@B144]). The EBNA1 protein is expressed in all forms of EBV-related malignancy, making it an ideal candidate for immunotherapy; efforts to target a CD8 CTL response against the protein have been challenging, however, as a glycine-alanine repeat within the protein prevents presentation by MHC class I ([@B145]). Several groups have since shown that CD4 CTL can recognize EBNA1 epitopes and kill infected B cells ([@B76], [@B142], [@B144]). Interestingly, these CD4 CTL clones exhibited distinct phenotypic and functional characteristics compared to the influenza-specific CD4 CTL described previously; they exhibited a Th0 phenotype (with secretion of both IFN-γ and IL-4) and killed infected cells *via* Fas/FasL interactions rather than perforin secretion ([@B144]).

The relevance of these responses *in vivo* and in immunotherapy approaches, however, is called into question with the observation that EBNA1-specific CD4 CTL identified *in vitro* only poorly recognize native lymphoblastoid cell lines (LCLs) expressing EBNA1. Although this is commonly attributed to the protein's limited access to the MHC class II presentation pathway ([@B146]), a recent study identifies EBV miRNA expression as a novel immune evasion mechanism ([@B147]). EBV-derived miRNAs suppress Th1 differentiation pathways, interfere with MHC class II antigen presentation, and subsequently inhibit the activation of EBV-specific CD4 CTL. Encouragingly, Long et al. ([@B143]) recently demonstrated that CD4 CTL responses to a variety of lytic cycle antigens could efficiently recognize EBV-transformed LCLs containing only a small proportion of lytically infected cells. This CD4 response was possible due to the uptake of lytic antigens by latently infected cells, which then efficiently processed and displayed epitopes for CD4 recognition. CD4 CTL also responded to a substantially broader array of lytic cycle proteins across the immediate early, early, and late phases compared to CD8 CTL, which skew toward immediate early proteins. Several other studies have identified cytolytic CD4 responses to epitopes in the lytic protein BHRF1 (in HLA-DR\*0401-positive subjects) ([@B24]), as well as BLLF1, BALF4, and BZLF1 ([@B148]). *In vitro*, T cell recognition of BLLF1/BALF4/BZLF1 epitopes did not require productive infection, could occur in the context of viral transfer to bystander B cells and was capable of controlling proliferation of infected B cells *via* cytolysis ([@B148]), further confirming the therapeutic potential of CD4 CTL ([@B149]).

Therapeutic induction of effector CD4 T cell responses against EBV antigen to fight malignancies demonstrate promise in animal models; effective killing of virus-induced tumor cells following treatment with a CD137 agonist was seen in CD8 T cell-deficient mice ([@B150]). In the same murine model, CD137 signaling improved expression of pro-inflammatory cytokines and cytotoxic effector molecules in tumor-specific CD4 T cells, coincident with upregulation of Eomes and Tbox ([@B151]); these cells were able to kill virus-induced tumor cells *in vivo*. Moving in the preclinical direction of immunotherapy, EBNA1-specific CD4 T cells expressing effector cytokines and GzmB were induced following therapeutic EBV vaccination against rhEBNA1 fused to the herpes simplex virus glycoprotein D, in rhesus macaques infected with lymphocryptovirus ([@B152]). Phase I human trials focus upon nasopharyngeal carcinoma, a malignancy more prevalent in South East Asia ([@B153]). Recombinant vaccinia virus encoding EBNA1 and LMP2 was applied intradermally to boost immunity in EBV-associated nasopharyngeal carcinoma patients. T-cell responses were detected postvaccination by IFN-γ ELISpot and mapped to MHC class II epitopes for both vaccine-encoded proteins ([@B154]). Constructs specifically designed to target CD4 T cell response to EBV by encoding the CD4 T cell epitope enriched C-terminal EBNA1-fused to LMP2 ([@B153]), demonstrated functional differentiation and *in vitro* targeting of antigen-loaded cells, though epitope mapping was not performed. Efficacy studies thus demonstrate generation of CD4 CTL, which target antigen constitutively expressed in EBV-associated cancer, giving promise to development of Phase II trials and complementary therapies that lead to remission.

Infections in Which CD4 CTL may be Pathogenic {#S8}
=============================================

Dengue Virus {#S8-1}
------------

The fact that DENV infection elicits cytotoxic CD4 T cell responses in humans has been known since 1989 ([@B30]), whether these cells are protective or pathogenic is currently unclear. Secondary infection with a dengue serotype different from the primary infection can lead to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Multiple early studies demonstrated that DENV-specific CD4 CTL are cross-reactive against multiple serotypes ([@B30]--[@B33]), leading to the hypothesis that CD4 cytotoxicity may contribute to DHF and DSS. Additionally, Gagnon et al. ([@B77]) reported that capsid protein-specific CD4 CTL could mediate killing of both APCs (*via* perforin expression) and HepG2 liver cells (*via* Fas/FasL recognition). The authors concluded that the killing of liver cells may also implicate CD4 CTL in the manifestation of liver disease that is frequently observed upon secondary infection. More recently, however, Weiskopf et al. performed a more comprehensive characterization of *ex vivo* DENV-specific CD4 T cells and confirmed that these cells are strongly biased toward a cytolytic phenotype ([@B155]). Repeated dengue infection was associated with an expansion of DENV-specific CCR7−CD45RA+ CD4 memory cells that expressed CD8α, CD107a, perforin, granzyme, Eomes, and CX3CR1 and were capable of killing target cells. In contrast to previous studies, Weiskopf suggested that CD4 CTL may play a role in reducing the severity of dengue infection due to the observation that the frequency of these cells is greater among individuals carrying the protective HLA-DRB1\*04 allele. It is unclear whether any of the individuals with multiple dengue infections in this study experienced DHF/DSS; comparisons of CD4 CTL activity not only among individuals with or without protective HLA alleles but also among those with or without severe complications of secondary infection will be highly informative in the future.

Viral Hepatitis {#S8-2}
---------------

Relatively little is known about CD4 CTL responses in viral hepatitis. A comparison of individuals infected with Hepatitis B virus (HBV), HCV, and HBV/Hepatitis D virus (HDV) co-infection revealed a variable, but significantly increased, proportion of CD4 T cells expressing perforin *ex vivo* compared to healthy controls; in some individuals, up to 25% of bulk CD4 T cells were perforin+ ([@B28]). Perforin levels were significantly higher in HDV-infected subjects compared to HBV or HCV monoinfection and were, in fact, comparable to HIV-infected patients. As previously mentioned, the fact that liver hepatocytes may be a target of chronically induced CD4 CTL raises the issue of whether these cells contribute to immunopathology. Among all hepatitis patients, CD4 perforin expression correlated with aspartate aminotransferase levels and platelet counts and was highest among patients with the most advanced disease. Additional work, including longitudinal studies, will be required to better define the role of CD4 CTL in viral hepatitis, as well as the antigen specificity of these CTL. While one study describes an HCV-specific TCR that can confer cytolytic activity when transduced into CD4 T cells ([@B156]), the *in vivo* CD4 CTL repertoire generated during chronic hepatitis infection remains to be described.

Other Viral Infections {#S9}
======================

Poxviruses---Ectromelia and Vaccinia Viruses {#S9-1}
--------------------------------------------

CD4 CTL play an important role in the response to ectromelia virus, the pathogen responsible for mousepox. During acute ectromelia virus infection, a large number of CD4 T cells that express GzmB were found in the draining lymph nodes and liver of infected mice ([@B157]). These CD4 CTL demonstrated *in vivo* MHC II-restricted CTL activity that was perforin dependent. Defective control of ectromelia virus was found in mice with a specific deficiency of perforin in their CD4 T cells ([@B157]). Comparisons of ectromelia virus and vaccinia virus (the active constituent of the smallpox vaccine) infection in mice showed that ectromelia virus induced significantly more CD4 CTL than vaccinia with different epitope-specific CD4 cells exhibiting different cytotoxic frequencies ([@B158]). These results reveal that not all viral infections result in the generation of CD4 CTL with the same cytolytic ability.

The first descriptions of CD4 CTL in response to vaccinia virus in humans were from Littaua et al. and Demkowicz et al. ([@B159], [@B160]) who established CD3+CD4+CD8−Leu11− cytotoxic T cell lines and clones from vaccinated individuals. These clones and cell lines were vaccinia virus-specific and lysed target cells in an HLA class II-restricted manner. The mechanism of lysis was not established for these CD4 cell lines or clones; however, further studies of vaccinia virus-specific cytotoxic CD4 T cell lines have shown that lysis was inhibited by concanamycin A, an inhibitor of perforin, but not by an anti-Fas antibody ([@B161]). Zaunders et al. ([@B14]) have shown that activated CD4 T cells detected in the early primary immune response to immunization with vaccinia virus expressed the cytotoxic granule marker TIA-1. The IFN-γ+ vaccinia virus-specific CD4 T cells detected in this study appeared as early as 11 days postvaccination and were shown to be predominantly TIA-1+ and were CD57−. A more recent study of the genetic profile of these activated CD4 T cells in the acute response to vaccinia virus has shown that these cells have a prominent CTL profile with upregulation of CTL associated genes including GzmK GzmA, KLRB1/CD161, Rab27a, and granulysin ([@B15]). The genes for perforin and TIA-1 were also upregulated; interestingly, the expression of *GzmB* was downregulated. From the same study, vaccinia virus-specific CD4 T cell lines were generated from a vaccinated individual at 13 days and 12 months postvaccination. These lines were shown to upregulate the machinery of cytotoxic degranulation and subsequently lyse HLA-matched target cells, loaded with autologous vaccinia virus peptides ([@B15]).

Parvovirus {#S9-2}
----------

Human parvovirus B19 is a relatively common viral infection; although it is often asymptomatic, infection has been associated with aggravation of rheumatoid arthritis and systemic lupus erythematosus ([@B162]). CD4 cells from B19 seropositive individuals exhibit perforin and GzmB expression following antigenic stimulation and are cytotoxic, albeit following a relatively long 5-day stimulation ([@B34]). Interestingly, CD4 CTL in seropositive donors co-expressed IL-17 and CD56, two markers not previously associated with cytotoxic CD4 responses in other infections. The importance of these markers in CD4 CTL function and immunity to parvovirus B19 remains to be explored.

Vaccine-Induced CD4 CTL {#S10}
=======================

The mounting evidence that CD4 CTL are an important component of protective immunity against many infectious diseases suggests that eliciting such cytotoxic responses may boost vaccine efficacy against infections such as HIV and influenza. Indeed, Watson et al. ([@B163]) recently showed that the highly effective live-attenuated yellow fever vaccine elicits both CD8 and CD4 CTL responses in a mouse model of infection. Both immune sera and CD4 T cells were required for full protection against fatal infection, which closely mimics the requirements described by Brown et al. ([@B74]) for protection from fatal influenza infection and provides support for the goal of vaccine-elicited CD4 CTL responses.

Based on the evidence suggesting that the induction of Th1 responses at the site of infection in the context of IL-2 and an inflammatory signal should induce an optimal CD4 CTL response against influenza infection, Vogel and Brown ([@B164]), tested the efficacy of intranasal immunization of inactivated influenza with CpG adjuvant. This vaccine induced high levels of inflammatory and chemotactic transcripts and significantly reduced viral burden in response to heterologous challenge. Compared to vaccination with inactivated influenza alone, the addition of CpG induced significantly higher GzmB expression in lung CD4 T cells, which persisted after challenge with lethal PR8 infection. This approach may therefore be a good candidate for generating adaptive memory responses at the site of infection that are capable of limiting the replication of heterotypic viruses, particularly if well-conserved epitopes were chosen for vaccination. To that end, Babon et al. ([@B165]) identified a CD4 T cell epitope in the fusion peptide of the HA that is conserved across all influenza A HA subtypes as well as the influenza B HA protein. A CD4 T cell clone recognizing this epitope exhibits cytotoxicity to a variety of influenza strains, including avian H5N1 virus. Importantly, the CD4 clone is likely restricted by a common HLA allele, making this epitope an intriguing candidate for future vaccine studies. Using TLR-stimulating adjuvants to boost flu-specific CTL responses to conserved epitopes represents a novel avenue for future vaccine candidates ([@B166]).

The induction of CD4 CTL responses by an HIV vaccine may be similarly advantageous. Terahara et al. studied vaccine-induced SIV-specific CD4 T cell responses and found that CD107a+ vaccine-elicited CD4 T cells were more resistant to SIV infection than CD107a- cells, suggesting that CD4 CTL may be an ideal response to elicit during vaccination in order to avoid generating increased levels of target cells ([@B167]). While evidence does suggest the protective role of CD4 CTL induced early after infection, less work has focused on determining the efficacy of vaccine-induced CD4 CTL in humans. Vaccine-induced cell-mediated responses elicited by the modestly protective RV144 vaccine were assessed in HIV-uninfected individuals, and Env-specific polyfunctional effector memory CD4 T cells were detected along with high expression of CD107a in proliferating HIV-specific CD4 T cells ([@B17]). HIV-specific CD4 T cell lines grown from HIV-uninfected vaccinees were found to be polyfunctional and have cytolytic capacity in response to an Env peptide pool, suggesting that the vaccine did elicit some cytotoxic CD4 responses ([@B17]). Although not specifically linked to CD4 CTL, it is of interest to note that recent reanalysis of data from the original RV144 correlate analysis ([@B168]) has shown that two vaccine-induced polyfunctional CD4 T cell subsets are associated with decreased risk of HIV infection ([@B169]). A more specific analysis of CD4 CTL activity in infected and uninfected vaccine recipients is warranted in future trials.

Conclusion/Future Directions {#S11}
============================

Major histocompatibility complex class II-restricted CD4 T cells with a cytotoxic phenotype are a prominent component of the antiviral immune response. These CD4 CTL have been identified in response to a plethora of viral infections affecting mice, non-human primates, and humans, and many aspects of their role in immunity remain unanswered. Despite the apparent importance of cytotoxic CD4 T cells in the immune response to many viruses, there is to date a paucity of reports in the literature of these cells placing any immune pressure on the virus as evidenced by CD4 CTL escape. The lack of these data is intriguing and should be further studied to understand the immune pressure exerted by the antiviral CD4 CTL response. With regard to T regulatory cells, the role of granzymes in regulatory function needs to be confirmed, and differences between studies in humans and mice require clarification.

Future studies of CD4 CTL should concentrate on single-cell transcriptomics to further understand and define the CD4 CTL lineage. A large body of studies have been conducted on murine CD4 CTL; however, it is important to understand if such studies provide equivalent and translational information about human CD4 CTL. Further studies on how best to generate antigen-specific CD4 CTL *in vitro* for cell therapy and immunization are also warranted.
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